TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28107643

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study: 24286968

Group type: EXPERIMENTAL
Intervention: Codeine-containing cough syrups (CCS) users
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 30
Study: 23072247

Group type: EXPERIMENTAL
Intervention: Family-based intervention targeting parents with general information about nutrition and exercise recommendations through a website and group intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Family-based intervention targeting parents
Number of subjects: 240
Study: 20686477

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice-daily (b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in daily steady-state AUC(ss) of 1 microg x h/ml
Number of subjects: 0
Study: 17715838

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 15033968

Group type: EXPERIMENTAL
Intervention: LHTL (live high, train low)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 13

Group type: COMPARATOR
Intervention: LHTL and Control (Con)
Number of subjects: 13
Study: 12079251

Group type: EXPERIMENTAL
Intervention: Combined intervention (Life Skills Training and Strengthening Families Program)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LST only
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 10449212

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate aerosol (ISA) 2.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 60
Study: 7789487

Group type: EXPERIMENTAL
Intervention: 1 ppm NO2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 20
Study: 2169714

Group type: EXPERIMENTAL
Intervention: nedocromil sodium 1% nasal solution (Tilarin, QID, Fisons plc)
Number of subjects: 177

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 177
Study: 7449793

Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30347019

Group type: EXPERIMENTAL
Intervention: Alisertib plus paclitaxel
Number of subjects: 191

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 191
Study: 28341120

Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thyroplasty type I and type IV
Number of subjects: 20
Study: 26217533

Group type: EXPERIMENTAL
Intervention: Investment based intervention (patients rate and describe their investment before surgery and at 3 and 6 months post-surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investment based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23872464

Group type: EXPERIMENTAL
Intervention: 1 mg APD421
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 5 mg APD421
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 20 mg APD421
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 21734596

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 10 mg
Number of subjects: 8
Study: 20180679

Group type: EXPERIMENTAL
Intervention: N-of-1 designs for the intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small sample prevention study methodology
Number of subjects: 0
Study: 17722827

Group type: EXPERIMENTAL
Intervention: Needling acupoints at the same nervous segment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine acupoint selection
Number of subjects: 116
Study: 16169160

Group type: EXPERIMENTAL
Intervention: Gabapentin 3200 mg (1600 mg bid)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 15475040

Group type: EXPERIMENTAL
Intervention: Health plan‐based lifestyle intervention focusing on diet (high calcium foods, fruits, and vegetables) and physical activity (high impact and spinal motion)
Number of subjects: 228
Study: 11053699

Group type: EXPERIMENTAL
Intervention: Grafted LIMA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ungrafted RIMA (Control)
Number of subjects: 29
Study: 8852410

Group type: EXPERIMENTAL
Intervention: 20 micrograms antigen load (group A)
Number of subjects: 507

Group type: COMPARATOR
Intervention: 10 micrograms antigen load (group B)
Number of subjects: 507
Study: 1800180

Group type: EXPERIMENTAL
Intervention: Topical cysteamine 0.2% six times a day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 5
Study: 6354644

Group type: EXPERIMENTAL
Intervention: One rubber band ligation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two rubber band ligations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Three rubber band ligations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multiple rubber band ligations (two or three)
Number of subjects: 100
Study: 30813805

Group type: EXPERIMENTAL
Intervention: 3D-printed cast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fiberglass cast
Number of subjects: 16
Study: 31415608

Group type: EXPERIMENTAL
Intervention: On-demand medication
Number of subjects: 0
Study: 28597542

Group type: EXPERIMENTAL
Intervention: GDPT (gemcitabine, cisplatin, prednisone, thalidomide)
Number of subjects: 103

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 103
Study: 26015316

Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate diet (diet HP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 211
Study: 24716721

Group type: EXPERIMENTAL
Intervention: Viewing pictures of a romantic partner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing pictures of an equally attractive and familiar acquaintance
Number of subjects: 0
Study: 21814190

Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) with efavirenz (EFV)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Efavirenz (EFV) without rifampicin (RIF)
Number of subjects: 182
Study: 18584227

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17552954

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD) for 12 months
Number of subjects: 43
Study: 15029330

Group type: EXPERIMENTAL
Intervention: Participatory education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11803715

Group type: EXPERIMENTAL
Intervention: Variolink High Viscosity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Enforce
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Geristore
Number of subjects: 26
Study: 9509564

Group type: COMPARATOR
Intervention: SIRS patients without acute renal failure (non-ARF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SIRS patients with acute renal failure (ARF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SIRS patients with ARF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SIRS patients (both ARF and non-ARF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SIRS patients with both ARF and ARDS
Number of subjects: 35
Study: 8092504

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 300 micrograms clonidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 450 micrograms clonidine
Number of subjects: 30
Study: 3170992

Group type: EXPERIMENTAL
Intervention: Allergoid treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 31112513

Group type: EXPERIMENTAL
Intervention: Standard report with additional epidemiological information
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard imaging report
Number of subjects: 247
Study: 27088370

Group type: EXPERIMENTAL
Intervention: External focus of attention (EFA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Internal focus of attention (IFA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control instructions
Number of subjects: 15

Group type: COMPARATOR
Intervention: Expert athletes
Number of subjects: 15
Study: 26330567

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1089
Study: 23544105

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1131
Study: 22340224

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 µg/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 µg/kg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 105
Study: 19057893

Group type: EXPERIMENTAL
Intervention: Thiamine therapy (3 x 100 mg capsules per day for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3 capsules per day for 3 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiamine therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiamine therapy and Placebo
Number of subjects: 40
Study: 17464511

Group type: EXPERIMENTAL
Intervention: Once-daily loratadine 10 mg-pseudoephedrine 240 mg sustained release tablets
Number of subjects: 48

Group type: COMPARATOR
Intervention: Twice-daily loratadine 5 mg-pseudoephedrine 120 mg combination tablets
Number of subjects: 48
Study: 14675743

Group type: EXPERIMENTAL
Intervention: Prolactin response to meta-chlorphenylpiperazine (m-CPP) challenge in borderline subjects with high HAM-A and HAM-D scores
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prolactin response to meta-chlorphenylpiperazine (m-CPP) challenge in borderline subjects with high BIS scores
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cortisol response to m-CPP challenge
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cholinergic and noradrenergic challenges
Number of subjects: 52
Study: 11843736

Group type: EXPERIMENTAL
Intervention: 15 degrees left table tilt position (n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Full left lateral position (n = 29)
Number of subjects: 60
Study: 9924909

Group type: EXPERIMENTAL
Intervention: Telephone interview (T)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Self-administration (S)
Number of subjects: 139
Study: 7774736

Group type: EXPERIMENTAL
Intervention: Prostin E2 and amniotomy later (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low amniotomy and oxytocin titration (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intra-cervical Foley balloon overnight followed by low amniotomy and oxytocin titration (Group C)
Number of subjects: 90
Study: 2183884

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily for 1 week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily for 2 weeks)
Number of subjects: 14
Study: 452602

Group type: EXPERIMENTAL
Intervention: L-dopa plus decarboxylase inhibitors (carbidopa, benserazide)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Madopar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Switching between Sinemet and Madopar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-dopa (plasma levels)
Number of subjects: 20
Study: 31470828

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 840
Study: 28056897

Group type: EXPERIMENTAL
Intervention: Integrated care model including screening for cardiovascular risk factors, lifestyle interventions, linkage to primary health care, and active follow-up of intervention adherence.
Number of subjects: 1480

Group type: EXPERIMENTAL
Intervention: Integrated care model (intervention group)
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 1480
Study: 26498238

Group type: COMPARATOR
Intervention: Placebo acupuncture (three times per week for three consecutive weeks)
Number of subjects: 86
Study: 23474270

Group type: EXPERIMENTAL
Intervention: Dietary intake of folate
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin C
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Dietary intake of calcium
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Dietary intake of protein
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Dietary intake of carbohydrates
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Meeting US dietary guidelines for fruit
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Meeting US dietary guidelines for vegetables
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Average daily energy intake
Number of subjects: 234
Study: 21441783

Group type: EXPERIMENTAL
Intervention: RV5 between doses 1 and 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RV5 between doses 2 and 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RV5 in Analysis B
Number of subjects: 0
Study: 19743457

Group type: EXPERIMENTAL
Intervention: CoQ10 at 2,700 mg/day for 9 months
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 17570973

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (n = 47)
Number of subjects: 98

Group type: COMPARATOR
Intervention: chloroquine (n = 51)
Number of subjects: 98
Study: 15117088

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg and 20 mg
Number of subjects: 566
Study: 11692016

Group type: EXPERIMENTAL
Intervention: Aspirin (n=49)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-dose low-molecular-weight heparin (LMWH) (n=86)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Both Aspirin and LMWH
Number of subjects: 135
Study: 9515282

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg bid)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg tid)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 78
Study: 8410124

Group type: EXPERIMENTAL
Intervention: Autologous BMT (95 patients)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Chemotherapy (96 patients)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT (group 1, 116 patients)
Number of subjects: 572
Study: 3511861

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31669503

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30614171

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 international units)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28419992

Group type: EXPERIMENTAL
Intervention: Extended slow-dose transfusion (ESDT), half an SDP unit administered over 4 hours
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard single-donor platelet (SDP) transfusions
Number of subjects: 49
Study: 25910523

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus‐eluting stents
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Cypher sirolimus‐eluting stents
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Early ST (≤30 days)
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Late ST (>30 and ≤360 days)
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Very late ST (>360 days)
Number of subjects: 8719

Group type: COMPARATOR
Intervention: Patients without ST
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Combined rates of cardiac death and myocardial infarction
Number of subjects: 8719
Study: 24220487

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 300 mg gabapentin (group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 100 mg chlorpromazine (group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (group E)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 mg dexamethasone (group D)
Number of subjects: 150
Study: 21435612

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 150
Study: 18562435

Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17374064

Group type: EXPERIMENTAL
Intervention: Open chamber device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Closed chamber device
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 10
Study: 15049988

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (maximum dose of 1 micro mol/L)
Number of subjects: 20
Study: 11386405

Group type: EXPERIMENTAL
Intervention: Isometric muscle strength measurements for 16 muscle actions around the knees and hips.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Indices of muscle strength derived from measurements (five alternative approaches).
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Comparison of muscle strength around affected joints vs. unaffected joints.
Number of subjects: 122
Study: 9149606

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/d for 4 days prior to exposure and 400 mg on exposure day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL) for 4 days prior to exposure and 400 mg on exposure day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 8498093

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 4

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 4
Study: 3559492

Group type: EXPERIMENTAL
Intervention: Knowledge of Family APGAR score (known group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unknown Family APGAR score (unknown group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with self-reported family dysfunction (APGAR < 6)
Number of subjects: 0
Study: 2506661

Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg on day 1, 50 mg on day 2) plus heparin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rt-PA (50 mg over 8 hours on days 1 and 2) plus heparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment (rt-PA plus heparin)
Number of subjects: 25
Study: 31801872

Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 156

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 156
Study: 30555009

Group type: EXPERIMENTAL
Intervention: Heavy physical exertion level ≥6 (exertion scale 1-8)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Dynamic exertion and isometric resistance
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Sedentary individuals (regular vigorous exertion <1 day weekly)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Frequent regular vigorous physical exertion (>4 days weekly)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Emotionally charged exertion
Number of subjects: 762
Study: 28931647

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (various doses)
Number of subjects: 35
Study: 24237752

Group type: EXPERIMENTAL
Intervention: Individual education and counselling
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 23436259

Group type: EXPERIMENTAL
Intervention: 0.5 mg zaleplon
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mg zaleplon
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg zaleplon
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 mg zaleplon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zaleplon (all doses)
Number of subjects: 40
Study: 21458802

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection
Number of subjects: 0
Study: 19151570

Group type: COMPARATOR
Intervention: Epirubicin preparation (FarmorubicinRTU)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of epirubicin (Farmorubicin)
Number of subjects: 97
Study: 16557544

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus ribavirin
Number of subjects: 119
Study: 15059413

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg, 20 mg, and 10 mg per day for 4 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii multiglycoside (TW, 30-60 mg per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA, 5-6 mg per kilogram of body weight per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF, 16-18 mg per kilogram of body weight per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (anti-thyroid drugs and levo-thyroxine)
Number of subjects: 75
Study: 10989721

Group type: EXPERIMENTAL
Intervention: Pefloxacin (15-20 mg/kg per day bid for 14-28 days) in combination with ceftazidime and amikacin
Number of subjects: 21
Study: 9315494

Group type: EXPERIMENTAL
Intervention: Trazodone 150 mg/d
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 8403134

Group type: EXPERIMENTAL
Intervention: 24 gauge Sprotte spinal needle
Number of subjects: 93

Group type: COMPARATOR
Intervention: 27 gauge Quincke spinal needle
Number of subjects: 93